Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.
Abstract: It is currently unknown if the intrathecal administration of a high dose of allogeneic mesenchymal stem cells (MSCs) is safe, how MSCs migrate throughout the vertebral canal after intrathecal administration, and whether MSCs are able to home to a site of injury. The aims of the study were: 1) to evaluate the safety of intrathecal injection of 100 million allogeneic adipose-derived MSCs (ASCs); 2) to assess the distribution of ASCs after atlanto-occipital (AO) and lumbosacral (LS) injection in healthy horses; and 3) to determine if ASCs homed to the site of injury in neurologically diseased horses. Six healthy horses received 100 × 10 allogeneic ASCs via AO (n = 3) or LS injection (n = 3). For two of these horses, ASCs were radiolabeled with technetium and injected AO (n = 1) or LS (n = 1). Neurological examinations were performed daily, and blood and cerebrospinal fluid (CSF) were evaluated prior to and at 30 days after injection. Scintigraphic images were obtained immediately postinjection and at 30 mins, 1 h, 5 h, and 24 h after injection. Three horses with cervical vertebral compressive myelopathy (CVCM) received 100 × 10 allogeneic ASCs labeled with green fluorescent protein (GFP) via AO injection and were euthanized 1-2 weeks after injection for a full nervous system necropsy. CSF parameters were compared using a paired student's t test. There were no significant alterations in blood, CSF, or neurological examinations at any point after either AO or LS ASC injections into healthy horses. The radioactive signal could be identified all the way to the lumbar area after AO ASC injection. After LS injection, the signal extended caudally but only a minimal radioactive signal extended further cranially. GFP-labeled ASCs were not present at the site of disease at either 1 or 2 weeks following intrathecal administration. The intrathecal injection of allogeneic ASCs was safe and easy to perform in horses. The AO administration of ASCs resulted in better distribution within the entire subarachnoid space in healthy horses. ASCs could not be found after 7 or 15 days of injection at the site of injury in horses with CVCM.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research paper assesses the safety and tracking of intrathecal administration of allogeneic mesenchymal stem cells in both healthy and diseased horses, their migration through the vertebral canal, and whether they can position themselves at the site of an injury.
Research Objectives
The research was conducted with three main objectives. Firstly, it aimed to determine the safety of injecting a high dose (100 million) of allogeneic adipose-derived mesenchymal stem cells (ASCs) intrathecally.
Secondly, the study aimed to observe how these ASCs are distributed after being injected in either the atlanto-occipital (AO) or the lumbosacral (LS) area in healthy horses.
Finally, the purpose of the study was to ascertain whether the ASCs hone towards the site of injury in horses suffering from neurological diseases.
Study Design and Methods
In the research, a total of six healthy horses were injected with the allogeneic ASCs. For two out of these six horses, the ASCs were labeled with technetium before being injected either at AO or LS.
Post this, daily neurological examinations were conducted and the blood and cerebrospinal fluid (CSF) were evaluated before and 30 days post-injection.
The distribution of these cells was then assessed through scintigraphic images obtained at different intervals after the injection.
Additionally, three diseased horses suffering from cervical vertebral compressive myelopathy (CVCM) were injected with green fluorescent protein (GFP) labeled ASCs and observed for one to two weeks before being euthanized for a complete nervous system examination.
Results and Findings
The study concluded that the injection of allogeneic ASCs was safe as there were no significant changes in blood, CSF, or neurological conditions in any of the horses.
Furthermore, the study found that the radioactive signal of ASCs could be traced to the lumbar area after an AO injection but only minimally after an LS injection.
However, the ASCs, labeled with GFP, could not be found at the site of disease in diseased horses even after a week or two weeks post-injection, indicating that the ASCs did not necessarily home to the site of injury.
The paper also noted that the intrathecal injection of ASCs was found to be easily performed in horses and that the AO administration of ASCs led to better distribution within the entire subarachnoid space in healthy horses.
Conclusions
The research concludes that the intrathecal injection of allogeneic ASCs seems to be safe and can be easily performed in horses.
However, although ASCs were well distributed within the subarachnoid space in healthy horses after AO administration, ASCs could not be found at the site of injury in horses with CVCM, suggesting that they may not home to the site of injury.
Cite This Article
APA
(2018).
Safety and tracking of intrathecal allogeneic mesenchymal stem cell transplantation in healthy and diseased horses.
Stem Cell Res Ther, 9(1), 96.
https://doi.org/10.1186/s13287-018-0849-6
ETHICS APPROVAL: The protocol (#18785, #18801) was reviewed and approved by the UC Davis IACUC on 2 June 2015. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
This article includes 67 references
Laroni A, de Rosbo NK, Uccelli A. Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection.. Immunol Lett 2015 Dec;168(2):183-90.
Wang S, Cheng H, Dai G, Wang X, Hua R, Liu X, Wang P, Chen G, Yue W, An Y. Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury.. Brain Res 2013 Sep 26;1532:76-84.
Sato M, Uchida K, Nakajima H, Miyazaki T, Guerrero AR, Watanabe S, Roberts S, Baba H. Direct transplantation of mesenchymal stem cells into the knee joints of Hartley strain guinea pigs with spontaneous osteoarthritis.. Arthritis Res Ther 2012 Feb 7;14(1):R31.
Xia P, Wang X, Lin Q, Li X. Efficacy of mesenchymal stem cells injection for the management of knee osteoarthritis: a systematic review and meta-analysis.. Int Orthop 2015 Dec;39(12):2363-72.
Zeira O, Asiag N, Aralla M, Ghezzi E, Pettinari L, Martinelli L, Zahirpour D, Dumas MP, Lupi D, Scaccia S, Konar M, Cantile C. Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings.. J Neuroinflammation 2015 Sep 29;12:181.
Dang S, Xu H, Xu C, Cai W, Li Q, Cheng Y, Jin M, Wang RX, Peng Y, Zhang Y, Wu C, He X, Wan B, Zhang Y. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis.. Autophagy 2014 Jul;10(7):1301-15.
Liu M, Zeng X, Wang J, Fu Z, Wang J, Liu M, Ren D, Yu B, Zheng L, Hu X, Shi W, Xu J. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis.. Stem Cell Res Ther 2016 Apr 23;7(1):63.
Karussis D, Petrou P, Kassis I. Clinical experience with stem cells and other cell therapies in neurological diseases.. J Neurol Sci 2013 Jan 15;324(1-2):1-9.
Silver J, Schwab ME, Popovich PG. Central nervous system regenerative failure: role of oligodendrocytes, astrocytes, and microglia.. Cold Spring Harb Perspect Biol 2014 Dec 4;7(3):a020602.
Tam RY, Fuehrmann T, Mitrousis N, Shoichet MS. Regenerative therapies for central nervous system diseases: a biomaterials approach.. Neuropsychopharmacology 2014 Jan;39(1):169-88.
Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke.. Stem Cells 2010 Jun;28(6):1099-106.
Kerkis I, Haddad MS, Valverde CW, Glosman S. Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges.. Stem Cell Res Ther 2015 Dec 14;6:232.
Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L, Stecco A, Tarletti R, Miglioretti M, Fava E, Nasuelli N, Cisari C, Massara M, Vercelli R, Oggioni GD, Carriero A, Cantello R, Monaco F, Fagioli F. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial.. Exp Neurol 2010 May;223(1):229-37.
Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, Yang YS, Suh JG, Lee BH, Jin HK, Bae JS. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation.. Neurobiol Aging 2012 Mar;33(3):588-602.
Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.. J Neurol Sci 2012 Feb 15;313(1-2):167-77.
Yousefifard M, Nasirinezhad F, Shardi Manaheji H, Janzadeh A, Hosseini M, Keshavarz M. Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model.. Stem Cell Res Ther 2016 Mar 8;7:36.
Hu DZ, Zhou LF, Zhu JH. Marrow stromal cells administrated intracisternally to rats after traumatic brain injury migrate into the brain and improve neurological function.. Chin Med J (Engl) 2004 Oct;117(10):1576-8.
Liu J, Han D, Wang Z, Xue M, Zhu L, Yan H, Zheng X, Guo Z, Wang H. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells.. Cytotherapy 2013 Feb;15(2):185-91.
Jung DI, Ha J, Kang BT, Kim JW, Quan FS, Lee JH, Woo EJ, Park HM. A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury.. J Neurol Sci 2009 Oct 15;285(1-2):67-77.
Chen BK, Staff NP, Knight AM, Nesbitt JJ, Butler GW, Padley DJ, Parisi JE, Dietz AB, Windebank AJ. A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting Phase I human trials.. Transfusion 2015 May;55(5):1013-20.
Zhang J, Huang X, Wang H, Liu X, Zhang T, Wang Y, Hu D. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy.. Stem Cell Res Ther 2015 Dec 1;6:234.
Meyerrose TE, Roberts M, Ohlemiller KK, Vogler CA, Wirthlin L, Nolta JA, Sands MS. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease.. Stem Cells 2008 Jul;26(7):1713-22.
Spriet M, Hunt GB, Walker NJ, Borjesson DL. Scintigraphic tracking of mesenchymal stem cells after portal, systemic intravenous and splenic administration in healthy beagle dogs.. Vet Radiol Ultrasound 2015 May-Jun;56(3):327-34.
Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, Shultz LD, Eagon JC, Wirthlin L, Sands MS, Hedrick MA, Nolta JA. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models.. Stem Cells 2007 Jan;25(1):220-7.
Bauer G, Dao MA, Case SS, Meyerrose T, Wirthlin L, Zhou P, Wang X, Herrbrich P, Arevalo J, Csik S, Skelton DC, Walker J, Pepper K, Kohn DB, Nolta JA. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.. Mol Ther 2008 Jul;16(7):1308-15.
Satti HS, Waheed A, Ahmed P, Ahmed K, Akram Z, Aziz T, Satti TM, Shahbaz N, Khan MA, Malik SA. Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study.. Cytotherapy 2016 Apr;18(4):518-22.
Villanova M, Bach JR. Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1.. Am J Phys Med Rehabil 2015 May;94(5):410-5.
Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, Sun L. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis.. Mult Scler 2009 May;15(5):644-6.
Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease.. Regen Med 2010 Nov;5(6):933-46.
Shyu WC, Lin SZ, Chiang MF, Su CY, Li H. Intracerebral peripheral blood stem cell (CD34+) implantation induces neuroplasticity by enhancing beta1 integrin-mediated angiogenesis in chronic stroke rats.. J Neurosci 2006 Mar 29;26(13):3444-53.
Jarocha D, Milczarek O, Wedrychowicz A, Kwiatkowski S, Majka M. Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury.. Cell Transplant 2015;24(4):661-72.
Sahraian MA, Mohyeddin Bonab M, Ahmadi Karvigh S, Yazdanbakhsh S, Nikbin B, Lotfi J. Intrathecal mesenchymal stem cell therapy in multiple sclerosis: a follow-up study for five years after injection. Arch Neurosci 2014;1:71–75.
Vernau W, Vernau KA, Sue Bailey C. Cerebrospinal fluid. In: Kaneko J, Harvey JW, Bruss ML, editors. Clinical biochemistry of domestic animals. 6. San Diego: Academic Press; 2008. pp. 769–819.
Lin P, Correa D, Kean TJ, Awadallah A, Dennis JE, Caplan AI. Serial transplantation and long-term engraftment of intra-arterially delivered clonally derived mesenchymal stem cells to injured bone marrow.. Mol Ther 2014 Jan;22(1):160-8.
Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, von Bonin M, Barbieri L, Halai K, Ward S, Weng L, Chakraverty R, Lombardi G, Watt FM, Orchard K, Marks DI, Apperley J, Bornhauser M, Walczak H, Bennett C, Dazzi F. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.. Sci Transl Med 2017 Nov 15;9(416).
Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.. Blood 2006 Sep 15;108(6):2114-20.
Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.. Cell Stem Cell 2009 Jul 2;5(1):54-63.
Sanchez-Diaz M, Quiñones-Vico MI, Sanabria de la Torre R, Montero-Vílchez T, Sierra-Sánchez A, Molina-Leyva A, Arias-Santiago S. Biodistribution of Mesenchymal Stromal Cells after Administration in Animal Models and Humans: A Systematic Review. J Clin Med 2021 Jun 29;10(13).
Dos Santos Machado JJ, Piñeiro BG, Ramos IP, de Souza SAL, Gutfilen B, Nicola MH, de Souza PRC, Cruz E, Goldenberg RC. Safety and Localization of Mesenchymal Stromal Cells Derived from Human Adipose Tissue-Associated Hyaluronic Acid: A Preclinical Study. Stem Cells Int 2020;2020:1823427.
Kim H, Na DL, Lee NK, Kim AR, Lee S, Jang H. Intrathecal Injection in A Rat Model: A Potential Route to Deliver Human Wharton's Jelly-Derived Mesenchymal Stem Cells into the Brain. Int J Mol Sci 2020 Feb 13;21(4).
Thomson AL, Berent AC, Weisse C, Langston CE. Intra-arterial renal infusion of autologous mesenchymal stem cells for treatment of chronic kidney disease in cats: Phase I clinical trial. J Vet Intern Med 2019 May;33(3):1353-1361.
Xu Y, Peng TT, Huang S, Guo X, Luo J, Peng T, Liu L, Han M, Gao T, Tang H, Zhang J, He L, Xu K. Repeated Intrathecal Stem Cells Optimize Neuroplasticity and Motor Function in Moderate-to-Severe Cerebral Palsy of Rats. Stem Cells Int 2025;2025:4337435.
Yun WS, Cho H, Jeon SI, Lim DK, Kim K. Fluorescence-Based Mono- and Multimodal Imaging for In Vivo Tracking of Mesenchymal Stem Cells. Biomolecules 2023 Dec 13;13(12).
Yuan X, Ding L, Deng DYB. [Research progress of hydrogel combined with mesenchymal stem cells in the treatment of spinal cord injury]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2021 Aug 25;38(4):805-811.